AMY-101

• Description:

  AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs) . AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation[1][2].

• Product Name Alternative:

  Cp40

• UNSPSC:

  12352209

• Target:

  Complement System; SARS-CoV

• Type:

  Peptides

• Related Pathways:

  Anti-infection; Immunology/Inflammation

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/amy-101.html

• Purity:

  99.86

• Solubility:

  H2O : 25 mg/mL (ultrasonic)

• Smiles:

  CN1C2=CC=CC=C2C(C[C@H]3C(N[C@H](C(N[C@H](C(N[C@H](C(N(CC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CSSC[C@@H](C(N[C@H](C(N3)=O)C(C)C)=O)NC([C@H]([C@@H](C)CC)NC([C@H](N)CC4=CC=C(C=C4)O)=O)=O)C(N(C)[C@H](C(N)=O)[C@@H](C)CC)=O)=O)CCCNC(N)=N)=O)CC5=CN=CN5)=O)C)=O)C)=O)CC6=CNC7=CC=CC=C67)=O)CC(O)=O)=O)CCC(N)=O)=O)=C1

• Molecular Formula:

  C83H117N23O18S2

• Molecular Weight:

  1789.09

• References & Citations:

  [1]Kajikawa T, et al. Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates. Mol Ther Methods Clin Dev. 2017 Aug 18;6:207-215.|[2] Mastaglio S, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Apr 29:108450|[3]Yanyan Liu, et al. Complement C3 Produced by Macrophages Promotes Renal Fibrosis via IL-17A Secretion. Front Immunol. 2018 Oct 22;9:2385.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Scientific Category:

  Peptides

• Clinical Information:

  Phase 2

• CAS Number:

  [1427001-89-5]